Recent life science and diagnostic acquisitions have included Beckman Coulter, Pall, and Cepheid. In early 2020, Danaher completed the acquisition of GE Biopharma, now called Cytiva, which fills ...

Danaher Corp (DHR) reports robust cash flow and strategic acquisitions, despite facing revenue headwinds and market ...

Cepheid's Multiplex Panel enables physicians ... talented team and strong balance sheet, all powered by the Danaher Business System, we feel well-positioned to deliver long-term shareholder ...

For 2025, Danaher's 3% core revenue growth outlook ... growth than we had anticipated, including at Cepheid where it expects a decline in respiratory sales. While we still expect some adjusted ...

Analysts' ratings for Danaher (NYSE:DHR) over the last quarter vary from bullish to bearish, as provided by 5 analysts. The table below provides a concise overview of recent ratings by analysts ...